R-CHOP in DLBCL: priming for success Comment

被引：3
|
作者：
Hertzberg, Mark [1 ]
机构：
[1] Prince Wales Hosp, Hong Kong, Peoples R China
来源：
BLOOD | 2022年 / 139卷 / 08期
关键词：
PHASE-III;
D O I：
10.1182/blood.2021013620
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Martin et al(1) report the results of a phase 1 study evaluating a novel strategy of epigenetic priming before rituximab plus cyclo-phosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) using the hypomethylating agent CC486, an oral azacitidine, as initial treatment in patients with high-risk diffuse large B-cell lymphoma (DLBCL) or grade 3B/transformed follicular lymphoma. The authors demonstrate that the addition of CC-486 to R-CHOP shows promising clinical antitumor activity with an acceptable safety profile.
引用
收藏
页码：1121 / 1122
页数：2
相关论文
共 50 条
  • [31] Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    Winter, Jane N.
    Weller, Edie A.
    Horning, Sandra J.
    Krajewska, Maryla
    Variakojis, Daina
    Habermann, Thomas M.
    Fisher, Richard I.
    Kurtin, Paul J.
    Macon, William R.
    Chhanabhai, Mukesh
    Felgar, Raymond E.
    Hsi, Eric D.
    Medeiros, L. Jeffrey
    Weick, James K.
    Reed, John C.
    Gascoyne, Randy D.
    BLOOD, 2006, 107 (11) : 4207 - 4213
  • [32] Thrombocytopenia As a Risk Factor for Developing Febrile Neutropenia in Patients with DLBCL Receiving R-CHOP Chemotherapy
    Bailey, Ryan Edward
    Bliven, Sean Patrick
    Narkhede, Mayur
    BLOOD, 2022, 140 : 12122 - 12124
  • [33] The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study
    Vidal, Liat
    Lando, Shany
    Vaxman, Iuliana
    Shochat, Tzippy
    Raanani, Pia
    Gurion, Ronit
    Gafter-Gvili, Anat
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 904 - 910
  • [34] Bcl-6 protein not a prognostic indicator in patients with DLBCL receiving R-CHOP therapy
    Nature Clinical Practice Oncology, 2006, 3 (8): : 413 - 413
  • [35] Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
    Sun, Na
    Zhao, Jinhua
    Qiao, Wenli
    Wang, Taisong
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [36] Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP
    Rushton, Christopher
    Arthur, Sarah E.
    Alcaide, Miguel
    Cheung, Matthew
    Thomas, Nicole
    Hilton, Laura K.
    Michaud, Neil R.
    Daigle, Scott
    Davidson, Jordan
    Bushell, Kevin R.
    Yu, Stephen
    Jain, Michael D.
    Shepherd, Lois E.
    Crump, Michael
    Mann, Koren Kathleen
    Kuruvilla, John
    Assouline, Sarit
    Cleary, Kirstie
    Cragg, Mark S.
    Scott, David W.
    Johnson, Nathalie
    Morin, Ryan D.
    BLOOD, 2019, 134
  • [37] Routine Prophylaxis of Pneumocystis Pneumonia from the Fourth Cycle of R-CHOP Regimen in DLBCL Patients
    Park, Silvia
    Kim, Seok Jin
    Kim, Won Seog
    BLOOD, 2017, 130
  • [38] For elderly, R-CHOP and maintain
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2012, 9 (10) : 551 - 551
  • [39] A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise
    Lue, Jennifer K.
    O'Connor, Owen A.
    LANCET HAEMATOLOGY, 2020, 7 (11): : E838 - E850
  • [40] R-CHOP与CHOP方案治疗生发中心和非生发中心来源DLBCL疗效评价
    彭鹏
    邹文蓉
    王瑜
    现代医药卫生, 2013, 29 (16) : 2467 - 2469
12345